We hypothesized that gadoxetate disodium-enhanced MRI may provide additional prognostic information and we aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker for non-invasive assessment of the expression of OATP1B3 in prostate tumors. This evidence concerns the gene SLCO1B3 and prostate carcinoma.